Robust Immunity Conferred by Combining COVID-19 Vaccine Platforms in Older Adults
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R
. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health Eur. 2021; 7:100150.
PMC: 8261633.
DOI: 10.1016/j.lanepe.2021.100150.
View
2.
Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S
. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478.
PMC: 7445431.
DOI: 10.1016/S0140-6736(20)31604-4.
View
3.
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz L, Vormehr M
. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021; 595(7868):572-577.
DOI: 10.1038/s41586-021-03653-6.
View
4.
Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S
. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535.
PMC: 8440177.
DOI: 10.1038/s41591-021-01464-w.
View
5.
van de Sandt C, Nguyen T, Gherardin N, Crawford J, Samir J, Minervina A
. Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan. Nat Immunol. 2023; 24(11):1890-1907.
PMC: 10602853.
DOI: 10.1038/s41590-023-01633-8.
View